Polyclonal Activation of B Cells by Lactate Dehydrogenase-Elevating Virus is Mediated by N-Glycans on the Short Ectodomain of the Primary Envelope Glycoprotein
References
Ahmed, R., and Oldstone, M. B. A., 1984, Mechanisms and biological implications of virus-induced B-cell activation. In Concepts in Viral Pathogenesis (A. L. Notkins and M. B. A. Oldstone. eds.), Springer Verlag. New York, pp. 231–238.
Cafruny, W. A., Heruth, D. P., Jaqua, M. J., and Plagemann, P. G. W., 1986, Immunoglobulins that bind to uncoated ELISA plates: appearance in mice during infection with lactate dehydrogenase-elevating virus and in human anti-nuclear antibody positive sera. J. Med. Virol. 19:175–186.
Chen, Z., Li, K., and Plagemann, P. G. W., 2000, Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein. Virology. 266:88–98.
Chen, Z., Li, K., Rowland, R. R. R., Anderson, G. W., and Plagemann, P. G. W., 1998, Lactate dehydrogenase-elevating virus variants: cosegregation of neuropathogenicity and impaired ability for high viremic persistent infection. J. Neurovirol. 4:560–568.
Coutelier, J.-P., Coulie, P. G., Wauters, P., Heremans, H., and van der Logt, J. T. M., 1990, In vivo polyclonal B-lymphocyte activation elicited by murine viruses. J. Virology. 64:5383–5388.
Coutelier, J.-P., and van Snick, J., 1985, Isotypically restricted activation of B lymphocytes by lactic dehydrogenase virus. Eur. J. Immunol. 15:250–255.
Faaberg, K. S., and Plagemann, P. G. W., 1995, The envelope proteins of lactate dehydrogenase-elevating virus and their membrane topography. Virology 212:512–525.
Faaberg, K. S., and Plagemann, P. G. W., 1997, ORF3 of lactate dehydrogenase-elevating virus encodes a soluble, nonstructural, highly glycosylated, and antigenic protein. Virology 227:245–251.
Hu, B., Even, C., and Plagemann, P. G. W., 1992, Immune complexes that bind to ELISA plates not coated with antigen in mice infected with lactate dehydrogenase-elevating virus: Relationship to IgG2a and IgG2b-specific polyclonal activation of B cells. Viral Immunol 5:27–38.
Janeway, C. A., Travers, P., Walport, M., and Capra, J. D., 1999, Immunobiology. 4th edn., pp. 3231–3323. Garland Publishing.
Li, K., Chen, Z., and Plagemann, P. G. W., 1999, High frequency genetic recombination of an arterivirus, lactate dehydrogenase-elevating virus, in mice and evolution of neuropathogenic variants. Virology 258:73–83.
Li, K., Schuler, T., Chen, Z., Glass, G. E. G., Childs, J. E., and Plagemann, P. G. W., 2000, Isolation of lactate dehydrogenase-elevating viruses from wild house mice and their biological and molecular characterization. Virus. Res., In press.
Li, X., Hu, B., Harty, J. T., Even, C., and Plagemann, P. G. W., 1990, Polyclonal B cell activation of IgG2a and IgG2b production by infection of mice with lactate dehydrogenase-elevating virus is partly dependent on CD4+ lymphocytes. Viral. Immunol. 3:273–288.
Notkins, A. L., Mergenhagen, S. E., Rizzo, A. A., Scheele, C., and Waldmann, T. A., 1966, Elevated y globulin and increased antibody production in mice infected with lactic dehydrogenase virus. J. Exper. Med. 123:347–356.
Plagemann, P. G. W., 1996, Lactate dehydrogenase-elevating virus and related viruses. In Virology, 3rd edn, (B. N. Fields, D. M. Knipe, & P. M. Howley, eds) Raven Press, New York, pp. 1105–1120.
Plagemann, P. G. W., Chen, Z., and Li., K., 1999, Polylactosaminoglycan chains on the ectodomain of the primary envelope glycoprotein of an arterivirus determine its neuropathogenicity, sensitivity to antibody neutralization and immunogenicity of the neutralization epitope. Curr.Top. Virol. 1:27–43.
Plagemann, P. G. W., Rowland, R. R. R., Even, C., and Faaberg, K. S., 1995, Lactate dehydrogenase-elevating virus— an ideal persistent virus? Seminars in Immunopathobiol. 17:167–186.
Rowland, R. R. R., Even, C., Anderson, G. W., Chen, Z., Hu, B., and Plagemann, P. G. W., 1994, Neonatal infection of mice with lactate dehydrogenase-elevating virus results in suppression of humoral antiviral immune response but does not alter the course of viremia or the polyclonal activation of B cells and immune complex formation. J. Gen. Virol. 75:1071–1081.